7 Results for "

Cynomolgus monkey tissues

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Cynomolgus monkey tissues" in MCE Product Catalog:

Cat. No.: HY-P99750
CAS No.: 1443004-16-7
Synonyms: CT-P23

Target:  

Influenza Virus

Research Areas:  

Infection

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
loading...
    loading...
Cat. No.: HY-10294
CAS No.: 362505-84-8
Purity:  99.58%
Synonyms: SB-462795
Target:  

Cathepsin

Research Areas:  

Metabolic Disease Cancer

Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
loading...
    loading...
Cat. No.: HY-P991169
CAS No.: 2955620-21-8
Synonyms: NXT007; RG6512; RO7589655

Target:  

Factor Xa Thrombin

Research Areas:  

Cardiovascular Disease

Zemocimig (NXT007) is an activated factor VIII mimetic antibody. Zemocimig binds to FX, FIXa and their activated forms to form a ternary complex, bridges FIXa and FX on the phospholipid surface, and restores intrinsic prothrombinase activity. Zemocimig induces thrombin generation, acts as a procoagulant, antifibrinolytic agent and hemostatic agent, and can shorten aPTT, increase fibrin deposition, correct clotting time, and reduce bleeding parameters. Zemocimig is applicable to the research of hemophilia A .
loading...
    loading...
Cat. No.: HY-162074
CAS No.: 2651908-78-8
Target:  

HIV

Research Areas:  

Infection

Nipamovir is an orally active anti-HIV prodrug. Nipamovir is cleaved in vivo by glutathione and other active thiols. Nipamovir inhibits the replication of HIV-1RF and HIV-192HT599 in cells, with EC50 values of 3.64 μM and 3.23 μM, respectively. Nipamovir can be used in studies related to HIV infection .
loading...
    loading...
Cat. No.: HY-10294R
CAS No.: 362505-84-8
Synonyms: SB-462795 (Standard)
Research Areas:  

Metabolic Disease Cancer

Relacatib (Standard) is the analytical standard of Relacatib (HY-10294). This product is intended for research and analytical applications. Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
loading...
    loading...
Cat. No.: HY-P992142
CAS No.: 3050549-24-8
Synonyms: ANX-007

Target:  

Complement System

Vonaprument (ANX-007) is an intravitreally injected C1q antibody fragment (with a molecular weight of approximately 48 kDa) and a human monoclonal antibody. Vonaprument inhibits the activation of the classical complement cascade by specifically recognizing the globular head of C1q and blocking substrate binding. After intravitreal injection, Vonaprument distributes to the retina, choroid and optic nerve, and achieves complete C1q target binding in the aqueous humor and retinal tissues. Vonaprument can be used in research related to neurodegenerative eye diseases such as age-related macular degeneration and glaucoma .
loading...
    loading...
Cat. No.: HY-187088
CAS No.: 1198309-73-7
Target:  

mGluR

Research Areas:  

Neurological Disease

AZD-8418 is an orally active positive allosteric modulator of metabotropic glutamate receptor 2 (mGluR2), with an EC50 of 0.86 μM for rat mGlu2 receptors. AZD-8418 reduces the in vitro binding level of [ 3H]AZ12559322 in prefrontal cortex brain tissues of non-human primates. AZD8418 enhances the inhibitory effect of the mGlu2/3 agonist DCG-IV (HY-101335) on field excitatory postsynaptic potentials (fEPSP) in rat hippocampal brain slices. AZD-8418 reduces nicotine self-administration behavior in rats, and blocks cue-induced reinstatement of nicotine-seeking and food-seeking behaviors. The attenuating effect on nicotine self-administration behavior develops rapid tolerance, while inhibition of food self-administration behavior requires chronic administration. AZD-8418 can be used in research related to nicotine dependence and neuropsychiatric disorders .
loading...
    loading...